Valneva and limmatech enter into a strategic partnership to accelerate the development of the world's most clinically advanced tetravalent shigella vaccine candidate

Saint-herblain (france) and schlieren (zurich), august 1, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company and limmatech biologics ag, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced that the companies have entered into a strategic partnership and exclusive licensing agreement for the development, manufacturing and commercialization of shigella4v (s4v), a tetravalent bioconjugate vaccine candidate against shigellosis.
VALN Ratings Summary
VALN Quant Ranking